VIL1 and intestinal cancer: The murine intestinal cancer cell line MouseT1 (from a Vil-Cre;BrafLSL-V637E/+;p53LSL-R172H/+ mouse), had similar sensitivity to combinatorial PLX4720/Gefitinib treatment as HT-29 (WiDr), one of the three human cell lines tested by Prahallad and colleagues (Figures 7A and 7B; inhibition of proliferation by 60%–70%).